Generic Epanova Availability
Last updated on Apr 10, 2024.
Epanova is a brand name of omega-3 polyunsaturated fatty acids, approved by the FDA in the following formulation(s):
EPANOVA (omega-3-carboxylic acids - capsule;oral)
-
Manufacturer: ASTRAZENECA
Approval date: May 5, 2014
Strength(s): 1GM CONTAINS AT LEAST 850MG OF POLYUNSATURATED FATTY ACIDS (discontinued) [RLD]
All of the above formulations have been discontinued.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Epanova. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
DPA-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form
Patent 10,117,844
Issued: November 6, 2018
Inventor(s): Maines Timothy J. & Machielse Bernardus N. & Mehta Bharat M. & Wisler Gerald L. & Davidson Michael H. & Wood Peter RalphDPA-enriched pharmaceutical compositions of polyunsaturated fatty acids in free acid form, therapeutic methods for their use, and processes for refining the compositions from fish oil are presented.
Patent expiration dates:
- January 4, 2033✓
- January 4, 2033
-
Patent 7,960,370
Patent expiration dates:
- December 20, 2026✓
- December 20, 2026
-
Type a gelatin capsule containing PUFA in free acid form
Patent 8,383,678
Issued: February 26, 2013
Inventor(s): Sachetto Jean-Pierre & Bufton Roly & Buser Thomas
Assignee(s): Chrysalis Pharma AGA pharmaceutical formulation comprising at least one omega-3 polyunsaturated fatty acid in free acid form or a pharmacologically acceptable derivative thereof is contained in a soft gelatin capsule characterized in that the capsule comprises gelatin extracted by an extraction process comprising acid pre-treatment of a collagen source. One advantage of the present invention over a soft gelatin capsule containing the same formulation but comprising gelatin extracted by an extraction process comprising alkali pre-treatment of the collagen source is that the present invention does not harden significantly over time and thus has a longer shelf life.
Patent expiration dates:
- February 7, 2025✓✓
- February 7, 2025
-
Type A gelatin capsule containing PUFA in free acid form
Patent 9,012,501
Issued: April 21, 2015
Inventor(s): Sachetto Jean-Pierre & Bufton Roly & Buser Thomas
Assignee(s): Chrysalis Pharma AGA pharmaceutical formulation comprising at least one omega-3 polyunsaturated fatty acid in free acid form or a pharmacologically acceptable derivative thereof is contained in a soft gelatin capsule characterized in that the capsule comprises gelatin extracted by an extraction process comprising acid pre-treatment of a collagen source. One advantage of the present invention over a soft to gelatin capsule containing the same formulation but comprising gelatin extracted by an extraction process comprising alkali pre-treatment of the collagen source is that the present invention does not harden significantly over time and thus has a longer shelf life.
Patent expiration dates:
- February 7, 2025✓✓
- February 7, 2025
-
DPA-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form
Patent 9,050,308
Issued: June 9, 2015
Inventor(s): Maines Timothy J. & Machielse Bernardus N M & Mehta Bharat M. & Wisler Gerald L. & Davidson Michael H. & Wood Peter RalphDPA-enriched pharmaceutical compositions of polyunsaturated fatty acids in free acid form, therapeutic methods for their use, and processes for refining the compositions from fish oil are presented.
Patent expiration dates:
- January 4, 2033✓
- January 4, 2033
-
DPA-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form
Patent 9,050,309
Issued: June 9, 2015
Inventor(s): Maines Timothy J. & Machielse Bernardus N M & Mehta Bharat M. & Wisler Gerald L. & Davidson Michael H. & Wood Peter RalphDPA-enriched pharmaceutical compositions of polyunsaturated fatty acids in free acid form, therapeutic methods for their use, and processes for refining the compositions from fish oil are presented.
Patent expiration dates:
- January 4, 2033✓
- January 4, 2033
-
Type A gelatin capsule containing PUFA in free acid form
Patent 9,132,112
Issued: September 15, 2015
Inventor(s): Sachetto Jean-Pierre & Bufton Roly & Buser Thomas
Assignee(s): CHYSALIS PHARMA AGA pharmaceutical formulation comprising at least one omega-3 polyunsaturated fatty acid in free acid form or a pharmacologically acceptable derivative thereof is contained in a soft gelatin capsule characterized in that the capsule comprises gelatin extracted by an extraction process comprising acid pre-treatment of a collagen source. One advantage of the present invention over a soft gelatin capsule containing the same formulation but comprising gelatin extracted by an extraction process comprising alkali pre-treatment of the collagen source is that the present invention does not harden significantly over time and thus has a longer shelf life.
Patent expiration dates:
- February 7, 2025✓✓
- February 7, 2025
More about Epanova (omega-3 polyunsaturated fatty acids)
- Epanova consumer information
- Check interactions
- Compare alternatives
- Imprints, shape & color data
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: nutraceutical products
Related treatment guides
Glossary
Term | Definition |
---|---|
Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.